October 15, 2024
Envol and members of the Envol team have been attending AAPS for many years, because of the unique nature of the group and the event they host every year (PharmSci 360). AAPS is a group that highlights a lot of discovery work, with many attendees focused on formulation and bioanalytical chemistry. As a lab that supports these sectors, it is important for Envol to be there and have representation.
We will be joined by our sister company, ODIN Biosciences, who will be representing a well-rounded set of biological matrices for bioanalytical and immunology assays, both from primates as well as humans and other species. ODIN provides a bioservice to that community, and they will have a booth just next to ours, representing the ability to support the industry through ex-vivo and vitro matrices that will support those types of assays. One of the main entities Envol works with as it relates to primates are companies that are developing biologics. Within the context of biologics, primates can play a very vital role, and we do a lot of work in antibodies because in biologics, antibodies, and tuned antibodies are some of the more common and prevalent drugs that have recently been approved and that are commonly in development these days. These type of studies have a fair amount of complexity to them and require a fair amount of species translatability when using preclinical models. This is important for us because a lot of our clients come to us for this.
Envol Will Present on Drug Metabolism and PBPK Modeling
Envol is partnering with Mammoth Preclinical Consulting on a presentation during this year’s AAPS event. Dr C. Edwin Garner, who serves as our consulting Director of DMPK and Translational Modeling, will co-present on approaches to tuning and developing therapies related to antibodies. This presentation will focus on utilizing drug metabolism, pharmacokinetics, and physiological-based pharmacokinetic modeling (PBPK) in cross species translation. Further, Envol will be showcasing the use nonclinical developmental data in the optimization of antibodies with a focus on the importance of disposition, metabolism, and dose setting in the models being utilized for antibody studies. This presentation compliments the Envol’s offerings and this presentation is a key reason we will be at AAPS this year.
You are invited to join the Envol and Mammoth teams for their presentation entitled “Tuning Antibody Drug Development Using Relevant Models and PBPK” on Tuesday at 2pm in Room 360 (on stage 2).
We also look forward to discussing the expansion of our technology and capabilities. Most attendees in the discovery space are interested in vendor flexibility and overall capabilities, so we have been investing quite a bit, ensuring we maintain the flexibility of our services by enhancing the training and capabilities of the organization. Many of our clients require special considerations and we are now providing imaging via complicated techniques like MRI and PET scanning, as well as complicated surgeries and other models that can be really important to our preclinical discovery package. These have all been added over the last year or so while we have been on this growth trajectory, so we are really looking forward to discussing these with our friends, colleagues and contacts at the show.
